PART I Item 1. B usiness. BUSINESS Overview We are a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients lives. Our clinical pipeline includes two clinical-stage product candidates, the CD47 blocker evorpacept and an epidermal growth factor receptor (EGFR)-targeted antibody drug candidate (ADC) ALX2004. Our lead product candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of...
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-09 | 2025-12-31 | 0001193125-26-098454 | EDGAR | 100K words |
| 2025-03-06 | 2024-12-31 | 0000950170-25-034761 | EDGAR | — |
| 2024-03-07 | 2023-12-31 | 0000950170-24-027955 | EDGAR | — |
| 2023-03-09 | 2022-12-31 | 0000950170-23-007013 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001564590-22-007364 | EDGAR | — |
| 2021-03-18 | 2020-12-31 | 0001564590-21-014169 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-07 | 2025-09-30 | 0001193125-25-272281 | EDGAR | 66K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-107303 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066894 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123290 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095391 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056953 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062929 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041319 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021247 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023237 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0000950170-22-015553 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0000950170-22-008499 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-27 | 0001193125-26-079342 | EDGAR | 3K words |
| 2026-01-30 | 0001193125-26-030579 | EDGAR | — |
| 2026-01-30 | 0001193125-26-030561 | EDGAR | — |
| 2026-01-21 | 0001193125-26-018094 | EDGAR | — |
| 2025-11-07 | 0001193125-25-271112 | EDGAR | — |
| 2025-09-12 | 0001810182-25-000006 | EDGAR | — |
| 2025-08-12 | 0000950170-25-107277 | EDGAR | — |
| 2025-06-12 | 0000950170-25-085364 | EDGAR | — |
| 2025-05-08 | 0000950170-25-066440 | EDGAR | — |
| 2025-04-25 | 0000950170-25-058687 | EDGAR | — |
97 total filings indexed. 69 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001810182 |
| Ticker | ALXO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.alxoncology.com |
| Listed | 2020-07-17 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report